Quotient Sciences

The company's business model centers on integrating services that are traditionally outsourced to separate entities, thereby simplifying the supply chain and accelerating development timelines. Its core service platform, Translational Pharmaceutics®, combines formulation development, real-time GMP manufacturing, and clinical testing into a single, seamless process. This integrated approach has been shown to shorten development timelines by an average of 12 months. Services include drug substance synthesis, formulation development for various dosage forms (oral, inhaled, parenteral), clinical trial manufacturing, and clinical pharmacology. The company serves a global client base ranging from small biotech firms to large multinational pharmaceutical companies.

Quotient Sciences has grown through strategic acquisitions, including Arcinova in 2021, which expanded its capabilities into drug substance manufacturing and bioanalysis. This move allowed for the full integration of drug substance, drug product, and clinical testing services under one organization. The company is led by CEO Thierry Van Nieuwenhove, who joined in October 2023, and operates from facilities in the UK and the US.